Centessa Pharmaceuticals (CNTA) Stock Overview
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CNTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.76 |
| 52 Week High | US$40.26 |
| 52 Week Low | US$10.45 |
| Beta | 1.26 |
| 1 Month Change | 44.11% |
| 3 Month Change | 77.34% |
| 1 Year Change | 252.80% |
| 3 Year Change | 943.57% |
| 5 Year Change | n/a |
| Change since IPO | 82.80% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Oct 28
Centessa Pharmaceuticals (NASDAQ:CNTA) Is Using Debt Safely
Jul 17Is There An Opportunity With Centessa Pharmaceuticals plc's (NASDAQ:CNTA) 50% Undervaluation?
Apr 19Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring
Dec 31Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
Sep 25Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Shareholder Returns
| CNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.6% | 3.4% |
| 1Y | 252.8% | 46.8% | 29.7% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| CNTA volatility | |
|---|---|
| CNTA Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CNTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 114 | Mario Accardi | centessa.com |
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
Centessa Pharmaceuticals plc Fundamentals Summary
| CNTA fundamental statistics | |
|---|---|
| Market cap | US$6.11b |
| Earnings (TTM) | -US$197.53m |
| Revenue (TTM) | US$15.00m |
Is CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTA income statement (TTM) | |
|---|---|
| Revenue | US$15.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.00m |
| Other Expenses | US$212.53m |
| Earnings | -US$197.53m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,316.88% |
| Debt/Equity Ratio | 20.9% |
How did CNTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 05:00 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Centessa Pharmaceuticals plc is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Guofang Li | Chardan Capital Markets, LLC |
| null null | Chardan Capital Markets, LLC |